Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Bought by Deutsche Bank AG

Deutsche Bank AG boosted its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 311.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 171,602 shares of the company's stock after buying an additional 129,936 shares during the quarter. Deutsche Bank AG's holdings in Dr. Reddy's Laboratories were worth $2,710,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Mercer Global Advisors Inc. ADV lifted its holdings in Dr. Reddy's Laboratories by 3.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 27,419 shares of the company's stock worth $433,000 after buying an additional 831 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Dr. Reddy's Laboratories by 423.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after buying an additional 1,507 shares in the last quarter. Glass Jacobson Investment Advisors llc lifted its holdings in Dr. Reddy's Laboratories by 400.0% during the 4th quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock worth $32,000 after buying an additional 1,600 shares in the last quarter. POM Investment Strategies LLC lifted its holdings in Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock worth $36,000 after buying an additional 1,820 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in Dr. Reddy's Laboratories by 461.0% during the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock worth $40,000 after buying an additional 2,093 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Price Performance

Shares of RDY opened at $14.34 on Thursday. Dr. Reddy's Laboratories Limited has a twelve month low of $12.26 and a twelve month high of $16.89. The firm's fifty day simple moving average is $13.54 and its 200-day simple moving average is $14.03. The firm has a market capitalization of $11.97 billion, a price-to-earnings ratio of 22.83 and a beta of 0.33. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The business had revenue of $996.17 million for the quarter, compared to analyst estimates of $83.70 billion. Equities analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, May 8th.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.